Another advancement is the development of CD19/CD20 dual‐targeted CAR‐NK cells to intensify cytotoxicity against acute lymphoblastic leukaemia (ALL), reducing the risk of tumour escape due to antigen diversity and improving the therapy's effectiveness (Pan et al., 2020; Qin et al., 2018; Ruella et al., 2016; Wang et al., 2020). This evidence concerns the gene CD19 and acute lymphoblastic leukemia.